Introduction

!
The field of Barrett's esophagus ablation has come a long way since the original pioneering work of Brandt and Berenson in the early 1990s [1, 2] . In fact, ablation is now viewed as a legiti− mate first−line treatment option for healthy pa− tients with high grade dysplasia and early adeno− carcinoma, based on studies performed to date. Furthermore, the notion of complete ablation of Barrett's esophagus has moved from concept to reality. That being said, many questions about endoscopic ablation of Barrett's esophagus re− main unanswered. This section will try to address the following issues regarding the endoscopic ab− lation of Barrett's esophagus: 1. Where have we been? 2. Where are we now? 3. What are currently unresolved issues in en− doscopic ablation? 4. What are potential solutions for these issues?
Where have we been? ! The concept of endoscopic ablation emerged in 1992 with the work of Brandt and then Berenson, who demonstrated that re−injury to metaplastic epithelium followed by healing in an environ− ment characterized by aggressive control of acid could lead to re−epithelialization with a neosqua− mous lining of the esophagus [1, 2] . That early concept gave rise an explosion of techniques and publications that all demonstrated the feasibility of endoscopic ablation, using methods such as la− sers, multipolar electrocoagulation, heater probe, argon plasma coagulation, radiofrequency abla− tion, cryotherapy, photodynamic therapy with ei− ther sodium porfimer or 5−aminolevulinic acid, and endoscopic mucosal resection. This early work also suggested that the biologic properties of the neosquamous epithelium were compar− able to those of the normal squamous lining of the esophagus [3] . These early studies, while innovative, were flawed. They were typically uncontrolled, single− center case series, characterized by short−term follow−up, variable and nonstandardized treat− ment and follow−up protocols, and different pri− mary end points as measures of success. There was only one randomized controlled trial in the early days of ablation therapy [4] . Furthermore, this early literature examined ablation in a het− erogeneous group of patients, having intestinal metaplasia without dysplasia, low grade and high grade dysplasia, and both superficial and more deeply invasive adenocarcinoma. This being the case, there was no agreement on the best way to evaluate these approaches. Was the goal a "bottom up approach" starting with intes− tinal metaplasia, or a "top down" approach start−
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ing with superficial carcinoma as recommended by the Amster− dam group [5] ? Furthermore, these reports and many editorials did not pay ade− quate attention to following rules of evidence in evaluating new treatment approaches. In particular, those involved in endo− scopic ablation repeatedly failed to recognize several important principles of evidence−based evaluation of new treatment mod− alities. First, nonrandomized trials routinely overestimate the benefit of therapy [6] . Secondly, proof of principle and larger studies, including randomized controlled trials, continued to ex− amine large numbers of patients without dysplasia. These stud− ies repeatedly failed to acknowledge that, assuming a risk reduc− tion of 50 % for the development of cancer, that is, from an esti− mated 0.50 % per year to 0.25 % per year, then the number needed to treat to prevent one cancer in nondysplastic Barrett's epithe− lium was approximately 400 [7] . Studies routinely found incomplete macroscopic regression of the Barrett's segment and buried intestinal metaplasia beneath the neosquamous epithelium; hence, not surprisingly, there were reports of subsquamous cancers developing in patients with previously nondysplastic Barrett's epithelium [8 ± 10] . Fur− thermore, persistent genetic abnormalities were noted after photodynamic therapy, despite histological downstaging from high grade dysplasia to lesser abnormalities, along with subse− quent redevelopment of high grade dysplasia [11] . Also, some authors demonstrated persistent molecular abnormalities in re− sidual dysplastic and nondysplastic epithelium after ablative therapy [12 ± 14] . Other complications were noted as well, in− cluding perforation, stricture formation, and prolonged photo− sensitivity. It also became clear that the homogeneous applica− tion of these techniques to the entire surface area of the esopha− gus was a challenge. Most importantly, ablation therapy in its early days was also hampered by the limited amount of data, derived from either an− imal or human studies, regarding the optimal dosing and admin− istration of a given technique to achieve the most beneficial depth of injury; such studies were the exception rather than the rule [15 ± 18] .
Where are we now?
The field of endoscopic ablation has matured considerably as we reach the end of 2008. Long−term studies extending over 5 years are now available, dealing with endoscopic mucosal resection, photodynamic therapy, and a combination of the two; these de− monstrate long−term survival comparable to that following esophageal surgery for high grade dysplasia or superficial carci− noma, and low rates of cancer−associated death [19] . A recent population−based study of patients with early esophageal cancer found long−term survival for patients managed with endoscopic therapy to be comparable to survival in those treated with surgi− cal resection [20] . Randomized controlled trials have now compared a variety of ablation techniques with one another. These clinical trials have highlighted the difficulty in obtaining complete endoscopic and histologic ablation with argon plasma coagulation, multipolar electrocoagulation, and photodynamic therapy with 5−aminole− vulinic acid [21 ± 23] . Randomized controlled studies have eval− uated photodynamic therapy and radiofrequency ablation com− pared with a strategy of continued surveillance for patients with high grade dysplasia and low grade dysplasia [24, 25] . These studies represent a dramatic improvement in the quality of the work in this field and demonstrate the potential as well as the limitations of these techniques. The 5−year results of a random− ized controlled trial of photodynamic therapy alone versus con− tinued surveillance for high grade dysplasia showed that at 5 years, complete ablation of high grade dysplasia was achieved in only 48 %, and progression to cancer occurred in 15 % [26] . While the results were superior to those of the control arm, one can argue that the "juice is not worth the squeeze" for this tech− nique, given the continued risk of cancer and need for surveil− lance, along with the cost and morbidity of this procedure. The 1−year results for radiofrequency ablation compared with sham therapy in high grade and low grade dysplasia have been sub− mitted for publication (N. Shaheen, personal communication). Multicenter studies are now the norm rather than the exception. These studies all demonstrate the long−term efficacy of endo− scopic therapy compared with other treatments for intraepithe− lial neoplasia. Furthermore, there is an emerging consensus on the need to completely remove all at−risk mucosa rather than leave any metaplastic epithelium behind. This has led to the in− creasing popularity of multimodal therapy with endoscopic mu− cosal resection plus either continued wide area endoscopic mu− cosal resection or thermal ablative techniques to eliminate the remaining at−risk mucosa. Recent studies now indicate that complete ablation of Barrett's esophagus with endoscopic mu− cosal resection in combination with radiofrequency ablation is now feasible (l " Fig. 1 ). In addition, new techniques are now routinely evaluated in ani− mal models to determine the depth and type of injury from var− ious ablative techniques, as well as the time course of the injury. The studies on radiofrequency ablation have involved a stepwise progression from animal studies, to human studies prior to eso− phagectomy, to human dosimetry studies, single−center studies, multicenter nonrandomized studies, and now multicenter ran− domized controlled trials [25, 27 ± 30] . This process has also led to modifications in the radiofrequency ablation technique and the development of the focal ablation device. Regardless of the eventual role of radiofrequency ablation, this series of studies il− lustrates the steps that need to be taken in the development and application of ablative technologies in the future. This is perhaps easier said than done, given the economic realities involved in the development of endoscopic therapeutic technologies. Never− theless, the importance of animal work prior to widespread clin− ical application cannot be overstated. The emergence of endoscopic mucosal resection as both a diag− nostic and therapeutic tool has changed the landscape of abla− tion therapy (l " Fig. 2 ). Endoscopic mucosal resection of visible lesions in patients with high grade dysplasia and superficial adenocarcinoma has come of age, thanks in part to the pioneering work of the Wiesbaden group which has demonstrated 5−year survival of 98 % for meti− culously selected patients with early esophageal adenocarcino− ma treated by endoscopic mucosal resection [31] . Endoscopic mucosal resection of visible lesions in patients with high grade dysplasia is now recommended in clinical practice guidelines [32] . Finally, the emerging concept of the combination of endoscopic mucosal resection of visible lesions with either circumferential endoscopic mucosal resection or thermal injury treatment of the remaining at−risk mucosa is becoming established. The ra− tionale for this relates to the high metachronous cancer rate found by the Wiesbaden group along with the concept that at− risk mucosa, with its persistent molecular abnormalities re− mains after endoscopic mucosal resection. In 2008, exciting work from the Amsterdam group described the technique of cir− cumferential and focal ablation in a small number of Barrett's patients with residual dysplasia after endoscopic mucosal resec− tion of visible lesions [33, 34] . Gondrie et al. found complete ab− sence of Barrett's epithelium, dysplasia, cancer, and buried intes− tinal metaplasia in all patients studied, at a median follow−up of 14 months. These findings suggest that the concept of complete ablation of Barrett's esophagus and superficial cancer is now fea− sible. It appears that many techniques evaluated to date have fallen by the wayside or are about to do so. These include multipolar elec− trocoagulation, the heater probe, argon plasma coagulation, la− ser treatment, and, in all likelihood, photodynamic therapy in its current variations. The reasons for the probable demise of these techniques include difficulty in obtaining uniform abla− tion, cost, side effects and persistent endoscopically evident or microscopic columnar epithelium after therapy. Current tech− niques still in play include radiofrequency ablation, cryotherapy, endoscopic mucosal resection, endoscopic submucosal dissec− tion, and combinations of these techniques. The only conceiva− ble role at present for techniques such as multipolar electrocoa− gulation and argon plasma coagulation is for dealing with small islands and areas of residual Barrett's esophagus after treatment with another, more effective modality. While no comparative data are available, studies to date suggest that the focal radiofre− quency ablation probe may be a better choice at present. It is now clear that for any technique to have value, it must be in− expensive, safe, simple to apply, require a limited number of ses− sions for application, completely eliminate columnar epithe− lium, eliminate or decrease cancer or progression risk, and pos− sibly decrease the need for surveillance. Furthermore, it is essen− tial that techniques provide a uniform application to the esoph− agus. This requires compensation for movement related to re− spiration and esophageal motility. With this in mind, the center− ing balloons used in photodynamic therapy and the balloon− based radiofrequency devices which isolate esophageal seg− ments during the ablation procedure are appealing features of those methods. We also need to keep in mind that the application of these tech− niques also requires rigorous patient selection, high quality ima− ging and staging prior to application, and meticulous long−term follow−up.
What are currently unresolved issues in endoscopic ablation? ! While the field of endoscopic ablation has advanced dramatical− ly in recent years, there is much we still need to know.
What is the role of cryotherapy?
Cryotherapy remains under study as an ablative technique, ei− ther as a stand−alone approach or in combination with endo− scopic mucosal resection. Animal studies have already been un− dertaken to determine depth of injury with this technique and the time course of the response to injury. However, data as to its efficacy in Barrett's esophagus are very limited. Johnston et al. studied 11 patients, of whom seven showed complete endo− system. d At 2 months after circumferential ablation, two small residual is− lets of Barrett epithelium were detected with narrow−band imaging, and treated with secondary focal ablation using the HALO 90 system (12−o'clock position). e, f At 2 months after the last ablation session, the esophagus has completely regenerated with normal−appearing neosquamous epithelium.
scopic and histologic reversal at 6 months [35] . Preliminary re− ports of cryotherapy were presented at Digestive Diseases Week (DDW) 2008 for a small group of patients with high grade dysplasia and cancer, and a randomized sham controlled study is now under way [36] . The appeal of cryotherapy is ease of use and relatively low cost. However, the uneven application inherent in spraying of the cryogen, rather than direct balloon−based application to isolated segments of the esophagus, is a matter of concern with this tech− nique besides the lack of published data.
What is the role of radiofrequency ablation?
Studies to date have evaluated radiofrequency ablation in both nondysplastic and dysplastic Barrett's epithelium. We now know that a combination of circumferential and focal probes provides optimal results, that this technique can be safely com− bined with endoscopic mucosal resection, and that buried intes− tinal metaplasia appears to be rare. We also know that this method does not completely eliminate cancer risk or progres− sion of low grade dysplasia to high grade dysplasia [25] . Finally, published results for radiofrequency ablation are primarily from centers of excellence. However, only a limited number of patients have been studied, we still do not know about either long−term results beyond 2.5 years, or the safety and efficacy of the technique when used out− side of expert centers. In contrast, longer−term results are avail− able for photodynamic therapy, which suggest a favorable out− come when it is compared with esophageal resection [19] .
What is the optimal role of endoscopic mucosal resection?
As mentioned above, endoscopic mucosal resection has come of age, either as a stand−alone technique or in combination with complete ablation of the Barrett's segment. The key unresolved issue is the role of circumferential endoscopic mucosal resec− tion. Studies to date suggest that circumferential endoscopic mucosal resection results in complete remission of intraepithe− lial neoplasia and Barrett's epithelium in 75 % to 100 % of patients [37 ± 40] . Complication rates vary, but early bleeding, the occa− sional perforation, and late strictures remain issues. Key unan− swered questions related to endoscopic mucosal resection in− clude the following:
1. What is the optimal technique? 2. Should it be limited to patients with nodules only, or should it be applied in patients with flat dysplasia? 3. What is the optimal role and setting for circumferential endoscopic mucosal resection? 4. What is the best way to avoid islands of residual epithe− lium between resection specimens? 5. Can complications, especially strictures, be avoided?
Where does endoscopic submucosal dissection fit in?
Endoscopic mucosal dissection has disseminated from Asia to Europe and North America. Studies suggest that it is feasible and effective in superficial adenocarcinoma of the gastroesoph− ageal junction [41] . This technique allows for en bloc removal of larger tumors and avoids the problems in interpreting the lateral margins of piecemeal endoscopic mucosal resection specimens. However, more data are needed and the issues that need to be addressed include training, optimal techniques, and improved equipment, as well as the duration of the procedure.
Patient selection
Which patient should get which therapy? Assuming equal endo− scopic skills, it remains important to know which endoscopic therapy should be applied to a given patient. Should endoscopic mucosal resection be limited to focal lesions only? What is the length threshold for circumferential endoscopic mucosal resec− tion? Who should undergo thermal techniques and what param− eters should be used to determine which patient should get which combination techniques? Is it time for aggressive ablation in patients with low grade or indefinite dysplasia? Most impor− tantly, the issue of nondysplastic Barrett's esophagus needs to be confronted. There are two schools of thought in this regard. The first holds that, given the low risk of progression to cancer in a nondysplas− tic patient with Barrett's esophagus, it is hard to justify an inter− vention unless it is safe, inexpensive, and easy to do. The other camp suggests that we should get rid of all Barrett's epithelium, providing the potential to decrease or eliminate surveillance in the future. However, there are no data at present to justify such an approach.
Acid suppression
Aggressive acid suppression is typically part of the treatment plan of endoscopic ablation. However, it is well recognized that normalization of esophageal acid exposure is difficult to achieve in Barrett's esophagus patients, even with high dose therapy [42] . Furthermore, studies have shown that Barrett's esophagus may be reversed with multipolar electrocoagulation therapy de− spite abnormal esophageal acid exposure [43, 44] . There is little if any proof that acid suppression or antireflux surgery prevents the development of cancer or dysplasia in the absence of endo− scopic ablation. Nevertheless, the conditions still exist in patients with Barrett's esophagus for the metaplastic epithelium to redevelop, and we still do not know the best way to prevent this on a long−term ba− sis. Should patients routinely receive double dose or single dose proton pump inhibitor therapy? Should pH or impedance−pH monitoring be used to guide therapy? Given the risks of surgery, it is hard to imagine that routine antireflux surgery in conjunc− tion with ablation will ever become a management strategy.
Buried intestinal metaplasia
While early data for radiofrequency ablation are promising, it is difficult to envisage that any technique will reliably eliminate all subsquamous intestinal metaplasia. Biomarker abnormalities persist in this epithelium, but we still do not know what degree of subsquamous columnar epithelium, if any, can be tolerated after ablation. Recent studies in a small number of patients with buried intestinal metaplasia after photodynamic therapy found that buried Barrett's epithelium had reduced crypt prolif− eration and near normal DNA content compared with pretreat− ment Barrett's epithelium, raising the question of the neoplastic potential of the buried Barrett's epithelium [45] . Furthermore, better techniques for detecting buried columnar epithelium are needed. Confocal endomicroscopy is one such technique under study. Molecular marker development would also be helpful.
What is the appropriate depth of injury?
We know surprisingly little about the target depth of ablative techniques. As mentioned above, limited animal and human data are available from the full thickness of the esophagus. Biop− sy work by Ackroyd et al. suggests that the thickness of Barrett's columnar epithelium is approximately 0.6 mm [46] . Recent work from Leedham et al. suggests that molecular abnormalities may arise in esophageal submucosal glands [47] . If abnormal− ities may in fact originate that deeply, the target depth of injury may need to be reconsidered.
The cardia
Several reports suggest that the cardia behaves in unexpected and potentially undesirable ways after ablation therapy. Nodules with high grade dysplasia or cancer may develop months to years after therapy [48, 49] . The reason for this is unknown. While squamous epithelium may develop below the gastro− esophageal junction after ablation, it is unclear what is the nat− ural history of that metaplastic mucosa [50] . Not only can prob− lems develop at the cardia but it is difficult to apply techniques such as radiofrequency ablation to the cardia, even with the focal probe, due to positioning and the anatomic alterations in the set− ting of a large hiatal hernia.
What happens to the esophagus?
To date, limited human data are available regarding the results of applying ablative techniques to the esophagus. Motility appears to be unchanged. Despite the assumption that multipolar elec− trocoagulation resulted in only superficial injury to the esopha− gus, in a single patient who had been treated with multipolar electrocoagulation, subsequent esophagectomy for complica− tions of antireflux surgery revealed complete elimination of intestinal metaplasia in the esophagectomy specimen but fibro− sis, friability, and extensive adhesions to the pleura of the intra− thoracic esophagus [51] .
Predictors of response
What factors predict whether a patient will respond to a given therapy? Possible variables include segment length, hiatal her− nia size, adequacy of acid suppression, and biomarker values. To date, one study has evaluated biomarkers as predictors of re− sponse to photodynamic therapy. Prasad et al. found that p16 loss, detected by fluorescence in situ hybridization of cytology specimens obtained prior to photodynamic therapy for high− grade dysplasia or intramucosal carcinoma, predicted a lesser response to photodynamic therapy [52] . While these factors are not ready for "prime time", future studies will need to carefully examine biomarkers or other patient factors that predict re− sponse.
What are potential solutions to these issues?
!
As we look to the future, there is a clear need for answers to the above questions. I agree with the view of the Amsterdam group that future studies should emphasize a "top down" approach to evaluate these interventions in patients with intraepithelial neo− plasia or dysplasia. More data, especially from long−term stud− ies, are clearly called for with regard to cryotherapy, radiofre− quency ablation, endoscopic mucosal resection, endoscopic sub− mucosal dissection, and combinations of these techniques. The promising pilot work from Amsterdam demonstrating complete Total Barrett Eradication review section 1045 ablation needs confirmation in a larger number of patients at other centers. There is a clear need for multicenter randomized clinical trials that compare these different approaches. These studies should also allow us to refine predictors of response, be they clinical, endoscopic, or biomarker. Furthermore, those involved in endoscopic ablation should de− velop some consensus on the components of pre−intervention staging and imaging along with post−intervention end points and surveillance. All parties need to acknowledge that given the high stakes involved in treating esophageal cancer, all bets are off with ablative technologies if endoscopists and patients do not adhere to rigorous and meticulous follow up protocols, the details of which need to be defined. While the future of natural orifice transluminal endoscopic sur− gery (NOTES) as applied to gastrointestinal endoscopy remains hazy, clearly one can anticipate the emergence of better "tools of the trade", especially for endoscopic mucosal resection and endoscopic submucosal dissection. We still need methods that reliably and predictably control the depth and homogeneity of injury to the esophagus. For any new technique that may be de− veloped, the need will continue for well−crafted animal studies to determine depth of injury and dosimetry, like those per− formed for cryotherapy and radiofrequency ablation. Barrett's esophagus does not develop in a vacuum. Other factors that contribute to cancer risk in Barrett's esophagus need to be studied in conjunction with ablation, including age, gender, obe− sity, tobacco use, hiatal hernia size, ongoing reflux, diet, and use of nonsteroidal anti−inflammatory drugs (NSAIDs), to name just a few. To accomplish these goals is a challenge in the best of circum− stances. Given the current global financial problems, provision of funding to achieve these goals will be problematic and will re− quire imaginative approaches. Synergies of funding that involve partnerships between governments, industries, and foundations should be sought.
